$4,150,000 of MERCK & CO INC lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals. Issues relating to, One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Cost and value of medicines: Drug pricing and reimbursement issues; FY-2027 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP). Issues relating to, Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes; Tax Cuts and Jobs Act (P.L. 115-97), provisions relating to tax reform. Issues relating to, Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill, 2026; Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026; Interior, Environment, and Related Agencies Appropriations Bill 2026."
You can find more data on corporate lobbying on Quiver Quantitative.
MRK Congressional Stock Trading
Members of Congress have traded $MRK stock 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 02/04.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 12/19, 11/18 and 0 sales.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
MRK Insider Trading Activity
MRK insiders have traded $MRK stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:
- JENNIFER ZACHARY (EVP, General Counsel) has made 0 purchases and 3 sales selling 121,573 shares for an estimated $14,485,690.
- ROBERT M DAVIS (Chairman, CEO & President) has made 0 purchases and 2 sales selling 47,434 shares for an estimated $5,599,327.
- CAROLINE LITCHFIELD (EVP & CFO) sold 41,997 shares for an estimated $5,023,311
- CHIRFI GUINDO (Chief Marketing Officer) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $4,836,339.
- RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) sold 37,685 shares for an estimated $4,557,024
- JOHANNES JACOBUS OOSTHUIZEN (President, U.S. Market) sold 15,000 shares for an estimated $1,827,991
- DEAN Y LI (Executive VP & President, MRL) sold 15,087 shares for an estimated $1,791,824
- DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) has made 0 purchases and 2 sales selling 13,614 shares for an estimated $1,329,564.
- DALTON E. III SMART (SVP Fin. - Global Controller) has made 0 purchases and 2 sales selling 6,400 shares for an estimated $765,920.
- CRISTAL N DOWNING (Chief Comm. & Public Afrs Ofcr) sold 7,085 shares for an estimated $616,395
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
MRK Hedge Fund Activity
We have seen 1,639 institutional investors add shares of MRK stock to their portfolio, and 1,585 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 59,566,057 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $6,269,923,159
- WELLINGTON MANAGEMENT GROUP LLP added 11,156,354 shares (+14.8%) to their portfolio in Q4 2025, for an estimated $1,174,317,822
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 8,764,580 shares (-46.8%) from their portfolio in Q4 2025, for an estimated $922,559,690
- CARDANO RISK MANAGEMENT B.V. removed 8,639,639 shares (-89.8%) from their portfolio in Q1 2026, for an estimated $1,037,836,634
- FMR LLC added 7,409,816 shares (+22.2%) to their portfolio in Q4 2025, for an estimated $779,957,232
- MILLENNIUM MANAGEMENT LLC added 6,036,983 shares (+790.8%) to their portfolio in Q4 2025, for an estimated $635,452,830
- JPMORGAN CHASE & CO removed 6,001,669 shares (-17.0%) from their portfolio in Q4 2025, for an estimated $631,735,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MRK Analyst Ratings
Wall Street analysts have issued reports on $MRK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 12/15/2025
- Wells Fargo issued a "Overweight" rating on 11/24/2025
To track analyst ratings and price targets for MRK, check out Quiver Quantitative's $MRK forecast page.
MRK Price Targets
Multiple analysts have issued price targets for $MRK recently. We have seen 18 analysts offer price targets for $MRK in the last 6 months, with a median target of $130.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $145.0 on 04/13/2026
- Chris Schott from JP Morgan set a target price of $135.0 on 04/06/2026
- Trung Huynh from RBC Capital set a target price of $142.0 on 03/30/2026
- Geoff Meacham from Citigroup set a target price of $125.0 on 03/20/2026
- Mohit Bansal from Wells Fargo set a target price of $150.0 on 03/12/2026
- Emily Field from Barclays set a target price of $140.0 on 02/20/2026
- Vamil Divan from Guggenheim set a target price of $140.0 on 02/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
